Fostamatinib in chronic immune thrombocytopenia: No comparison—added benefit not proven
Fostamatinib is approved for the treatment of chronic immune thrombocytopenia in adults who are refractory to other treatments (in particular to treatment with corticosteroids). The German Institute for Quality and Efficiency ...
Oct 6, 2020
0
1